Arrhythmogenic Right Ventricular Cardiomyopathy - Antiarrhythmic Therapy
Simon Ermakov1, Melvin Scheinman1
1Stanford University Hospital and Clinics, California, US.
Arrhythmia & Electrophysiology Review
|February 3, 2016
Summary
Arrhythmogenic right ventricular cardiomyopathy (ARVC) treatment aims to manage arrhythmias and prevent sudden death. Antiarrhythmic drugs like sotalol, beta-blockers, and amiodarone are key for symptom control and reducing ICD shocks.
Area of Science:
- Cardiology
- Genetics
- Electrophysiology
Background:
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited condition causing fibrofatty tissue replacement in the ventricles.
- This leads to ventricular arrhythmias, heart failure, and sudden cardiac death.
- Current management strategies focus on disease progression, arrhythmia burden, and preventing sudden death.
Purpose of the Study:
- To review the efficacy of antiarrhythmic medications in managing ARVC.
- To identify optimal drug therapies and combinations for arrhythmia suppression in ARVC patients.
Main Methods:
- Review of current literature on ARVC treatment modalities.
- Analysis of antiarrhythmic drug efficacy, including monotherapy and combination therapy.
- Evaluation of the role of implantable cardioverter-defibrillators (ICDs) and catheter ablation.
Main Results:
- Implantable cardioverter-defibrillators (ICDs) are proven to reduce mortality in ARVC.
- Antiarrhythmic medications are crucial for reducing morbidity and inappropriate ICD shocks.
- Sotalol, beta-blockers, and amiodarone show the most promise for arrhythmia suppression.
- Combination therapies, such as sotalol + flecainide and amiodarone + beta-blockers, are effective for refractory cases.
Conclusions:
- Antiarrhythmic drugs are vital adjuncts to ICDs in ARVC management.
- Specific agents and combinations offer effective arrhythmia control, improving patient outcomes.
- Personalized therapeutic approaches are necessary for optimal ARVC patient care.
Keywords:
Arrhythmogenic right ventricular cardiomyopathyantiarrhythmicarrhythmia managementmedical therapyright ventricular dysplasiasudden deathMore Related Videos
Related Concept Videos
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
907
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
907
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
2.6K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.6K
01:29Disturbances in Heart Rhythm
3.5K
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
3.5K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
4.1K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.1K
01:25Dysrhythmias VI: Management of Dysrhythmias
612
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
612